UNITED THERAPEUTICS CORP

CEO’s 10‑b‑5‑1 plan shows United Therapeutics shares bought at a 70% discount, with disciplined selling after earnings to boost liquidity and investor confidence.

Martine Rothblatt’s 10‑b‑5 buy of United Therapeutics shows confidence in the company’s pulmonary‑hypertension pipeline and future FDA approvals, while her structured sales balance profit‑realization and long‑term commitment.

United Therapeutics insider Rothblatt buys 9,500 shares at $146, underscoring confidence in its pipeline and market strategy for Opsumit®, while a scheduled option exercise may affect supply – a must‑watch for investors.

United Therapeutics insider trades signal a cautious yet optimistic move: CEO and EVP buy at 10‑b‑5‑1 prices, hinting at future growth from upcoming prostacyclin data.

United Therapeutics insider sale: CEO’s 10(b) 5‑1 plan explains the modest 9,500‑share sell‑off—no market‑moving impact, just routine liquidity.

Olian Judy D. sells 200 shares of United Therapeutics Corp. in a planned 10b5‑1 transaction—insider activity that signals routine portfolio rebalancing and long‑term confidence in the company’s pulmonary‑hypertension pipeline.

United Therapeutics’ insider buys signal confidence in its vascular pipeline. Discover how UTX‑001 and other agents could reshape PAH treatment and what safety data show.

Insightful look at United Therapeutics’ insider trades shows disciplined execution, steady growth, and confidence in its oral prostacyclin pipeline—no red flags, just strategic stability.

United Therapeutics insider buying shows leadership confidence—analyzing Benkowitz trades, strategic moves, and market conditions for investors.

Explore United Therapeutics’ insider sale, clinical impact and pipeline – why a 50‑share trade matters to clinicians and investors alike.